The 36-month beta value for XBIO is also noteworthy at 2.29. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for XBIO is 1.25M, and at present, short sellers hold a 0.28% of that float. The average trading volume of XBIO on June 25, 2025 was 11.51K shares.
XBIO) stock’s latest price update
Xenetic Biosciences Inc (NASDAQ: XBIO)’s stock price has soared by 333030 in relation to previous closing price of 2.74. Nevertheless, the company has seen a gain of 12.32% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-14 that Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma Ended the quarter with $5.2 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / May 14, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2025. Recent Highlights Announced that its collaboration partner, PeriNess Ltd.
XBIO’s Market Performance
XBIO’s stock has risen by 12.32% in the past week, with a monthly rise of 2.37% and a quarterly drop of -7.50%. The volatility ratio for the week is 6.97% while the volatility levels for the last 30 days are 5.61% for Xenetic Biosciences Inc The simple moving average for the past 20 days is 5.18% for XBIO’s stock, with a -13.59% simple moving average for the past 200 days.
Analysts’ Opinion of XBIO
Many brokerage firms have already submitted their reports for XBIO stocks, with Maxim Group repeating the rating for XBIO by listing it as a “Buy.” The predicted price for XBIO in the upcoming period, according to Maxim Group is $2.50 based on the research report published on January 08, 2020 of the previous year 2020.
XBIO Trading at 9.79% from the 50-Day Moving Average
After a stumble in the market that brought XBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.52% of loss for the given period.
Stock Fundamentals for XBIO
Current profitability levels for the company are sitting at:
- -1.5 for the present operating margin
- 0.77 for the gross margin
The net margin for Xenetic Biosciences Inc stands at -1.42. The total capital return value is set at -0.76. Equity return is now at value -53.16, with -48.31 for asset returns.
Currently, EBITDA for the company is -4.2 million with net debt to EBITDA at 1.33. When we switch over and look at the enterprise to sales, we see a ratio of -0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.20.
Conclusion
In summary, Xenetic Biosciences Inc (XBIO) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
